Taken together, these findings demonstrate that CMV inhibition can attenuate androgen signaling in CRPC and imply that CMV inhibition may have additive effects to androgen receptor‐targeting pharmaceutical compounds in CMV+ prostate cancer. The gene discussed is AR; the disease is prostate carcinoma.